University Lab Partners selected by CIMIT to partner in their project to support the NIH RADx initiative - POCTRN
null University Lab Partners selected by CIMIT to partner in their project to support the NIH RADx initiative
University Lab Partners Selected by CIMIT to Partner in their Project to Support the NIH RADx Initiative
ULP and CIMIT will partner to support the NIH RADx Initiative
University Lab Partners has been selected by the Boston-based Consortia for Improving Medicine with Innovation & Technology (CIMIT) to partner in their project to support the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, which is working to accelerate the commercialization and deployment of new COVID-19 testing technologies. The goal of RADxSM is to make millions of tests per week available to Americans, particularly those most vulnerable to and/or disproportionately impacted by COVID-19, and having even more tests available in time for the 2020–2021 flu season.
University Lab Partners is a Southern California based biotech/medtech incubator focused on accelerating the commercialization of innovative technologies. University Lab Partners is an independent, non-profit entity located adjacent to University of California – Irvine that actively brings together world-class academic and medical institutions, medical device and diagnostic testing industry partners, and investment community members from the Region to accelerate the launch of new companies, products and the creation of new jobs.
CIMIT was formed in 1998 as a "center without walls," linking four leading academic research centers in the greater Boston area. It now includes 13 of Boston's strongest academic medical centers, universities, and a growing network of national and international affiliates. Starting from a foundation in medical devices, diagnostics, and procedures, the scope has grown to address the full spectrum of medical innovation including e-health, drugs, and biologics
About the NIH RADx initiative:
NIH launched the Rapid Acceleration of Diagnostics (RADxSM) initiative to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The initiative leverages the existing NIH Point-of-Care Technology Research Network. The RADx initiative partners with federal agencies, including the Office of the Assistant Secretary of Health, Department of Defense, the Biomedical Advanced Research and Development Authority, and U.S. Food and Drug Administration. Learn more about the RADx initiative and its programs: https://www.nih.gov/radx.
RADx: Rapid Acceleration of Diagnostics
In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADxsm) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.
In the News
Two New Over-the-Counter At-Home COVID-19 Tests Brought to U.S. Market Quickly by Biden-Harris Administration
New HHS actions add to Biden administration efforts to increase access to easy-to-use over-the-counter COVID-19 tests
NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests
The need for new test verification and regulatory support for innovative diagnostics
NIH-funded screening study builds case for frequent COVID-19 antigen testing
RADx partnerships speed new COVID testing
Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort
Innovative COVID-19 Testing RADx Tech Reports Unveiled in Special Issue of IEEE Open Journal of Engineering in Medicine and Biology
Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured Smartphone-Based COVID-19 Rapid Test
RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing (Login Required)
VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19
Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing
COVID-19 Testing: Three Breakthrough Solutions in the RADx Initiative
NIH Director: Collaboration Amid Chaos, and Biden’s First 100 Days - How Francis Collins sees the COVID response changing with the new administration
The National Strategy From the COVID-19 Response and Pandemic Preparedness
Winners of HHS Design-a-thon to Develop Innovative Digital Health Tools for COVID-19 At-Anywhere Diagnostic Tests Announced